Welcome to our dedicated page for Caredx news (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on Caredx stock.
CareDx, Inc. (NASDAQ: CDNA) is at the forefront of transforming transplant patient care through its innovative surveillance management solutions. Dedicated to improving the lives of organ transplant patients, CareDx leverages the latest in genomics and bioinformatics technology combined with rigorous clinical evidence derived from trials and registries.
CareDx offers a suite of precision medicine solutions aimed at enhancing both pre- and post-transplant care. One of its flagship products, AlloSure®, is the first and only non-invasive blood test that directly measures allograft injury. This next-generation sequencing (NGS) based test detects donor-derived cell-free DNA (dd-cfDNA), providing clinicians with a powerful tool to identify organ injury and the probability of active rejection, particularly in kidney transplant patients.
The company's portfolio also includes AlloMap Heart, AlloSure Heart, and AlloSure Lung, which are dd-cfDNA solutions designed for heart and lung transplant recipients. These products underscore CareDx’s commitment to offering clinically differentiated, high-value healthcare solutions that span the entire transplant journey.
CareDx generates the majority of its revenue from the United States, with a significant portion coming from its testing services. Its product suite not only addresses the critical needs of transplant patients but also supports healthcare providers in delivering better patient outcomes through genomics-based information.
Recent achievements include the continued expansion of their product line and partnerships with leading healthcare institutions to further validate and implement their innovative diagnostic solutions. These efforts position CareDx as a leader in the field of transplant diagnostics and surveillance.
CareDx, Inc. (NASDAQ: CDNA) has announced the enrollment of the first patient in the ACROBAT study, which investigates the potential of the AlloHeme testing tool in predicting relapse for patients undergoing allogeneic hematopoietic cell transplants. This multicenter study aims to evaluate the effectiveness of AlloHeme, which uses next-generation sequencing to monitor donor and recipient cell levels, enhancing patient surveillance post-transplant. With around 10,000 such transplants annually in the U.S., the outcome of this study could significantly impact patient care and surveillance in this area.
CareDx, Inc. (Nasdaq: CDNA) announced it will report its financial results for Q2 2021 after market close on July 29, 2021. A conference call hosted by company management will follow at 1:30 p.m. PT (4:30 p.m. ET). Investors can participate by calling 877-705-6003 domestically or 201-493-6725 internationally, using Conference ID: 13721182. Live webcasts will be available on CareDx's investor relations website.
CareDx specializes in precision medicine solutions for transplant patients, emphasizing genomics-based information throughout the pre- and post-transplant journey.
CareDx has launched the AlloCare app on the Android Play Store, complementing its availability on iOS, aimed at assisting organ transplant patients in managing their health pre-and-post-transplant. This user-friendly app offers features such as medication management, lab appointment scheduling, and biometric tracking, effectively doubling the total addressable user base. The app's design was heavily influenced by input from transplant recipients and patient organizations, ensuring it meets the specific needs of users, whether they are awaiting a transplant or years post-operation.
CareDx, Inc. (Nasdaq: CDNA) has announced the appointment of Dr. Hannah Valantine to its Board of Directors. Dr. Valantine, a Professor at Stanford and former Chief Scientific Officer at NIH, is recognized for her leadership in transplant medicine and diversity initiatives. She has collaborated with CareDx on important publications related to transplant biomarkers. Her extensive clinical background and innovative approach will enhance CareDx's Scientific Advisory Committee and support the company's mission to improve patient care in the transplant community.
Reg Seeto, President and CEO of CareDx (Nasdaq: CDNA), will discuss telehealth innovations for transplant patient care at the AAKP 2021 Summit on June 17, 2021. The presentation, titled Improving Access to Transplant Care, highlights solutions like RemoTraC, AlloCare, and Tx Connect, which have become essential, especially during the COVID-19 pandemic. Seeto emphasizes that such technologies enhance patient access and care throughout the transplant journey. AAKP advocates for patient-centered innovations in the kidney care community.
CareDx, Inc. (Nasdaq: CDNA), a leader in precision medicine for transplant patients, will participate in the Raymond James 2021 Human Health Innovation Conference on June 21, 2021, at 10:40 a.m. Eastern Time. The event will be accessible via a live webcast on the company's investor relations site. CareDx specializes in developing clinically differentiated healthcare solutions and is known for providing genomics-based information for transplant patients. Further details can be found on their website.
CareDx is hosting a live webinar featuring professional golfer Erik Compton, a two-time heart transplant recipient, on June 15, 2021. The event aims to discuss Compton's career, transplant journey, and his advocacy for organ donation. Compton, the only professional golfer competing with a transplanted heart, emphasizes the importance of sharing experiences within the transplant community. The webinar is free and open to all, reflecting CareDx's commitment to connecting with transplant patients. For more details, visit CareDx's website.
CareDx, Inc. has highlighted the significance of equity in transplantation at the 2021 American Transplant Congress. Dr. Hannah Valantine's keynote lecture emphasized using genomics to address health disparities in organ transplantation. Valantine presented the AlloMap IMAGE trial as crucial for understanding minority population insights, with dd-cfDNA identified as a key tool for personalizing care. CareDx aims to ensure all end-stage disease patients have equitable access to transplant resources, showcasing its commitment to diversity in transplant medicine.
CareDx, Inc. (CDNA) has announced its acquisition of Transplant Hero LLC, a New York-based mobile application provider that assists transplant patients with medication management. This acquisition enhances CareDx's digital portfolio, complementing its existing AlloCare app. Transplant Hero’s app helps patients manage complex medication schedules, crucial for organ transplant recipients. The deal is expected to improve patient outcomes by expanding CareDx’s capabilities across various organ transplants, leveraging Transplant Hero's established presence in the transplant community.
CareDx announced its participation in the American Transplant Congress (ATC) 2021, showcasing data from the Kidney Outcomes with AlloSure Registry (KOAR). This study, the largest of its kind, enrolled over 1,500 kidney transplant patients across 50 centers. Key findings reveal improved one-year graft survival rates and a reduction in biopsy procedures compared to traditional methods. The presentation aims to highlight AlloSure's effectiveness in monitoring transplant health and its role in enhancing patient care.
FAQ
What is the current stock price of Caredx (CDNA)?
What is the market cap of Caredx (CDNA)?
What does CareDx, Inc. specialize in?
What is AlloSure®?
Which organs do CareDx's products focus on?
Where does CareDx generate most of its revenue?
What are some key products offered by CareDx?
How does CareDx support transplant patients?
What technology does CareDx use in its diagnostics?
Does CareDx collaborate with other healthcare institutions?
What kind of clinical evidence does CareDx generate?
What makes CareDx a leader in transplant diagnostics?
